PE20010346A1 - Un complejo de eletriptan y un derivado de ciclodextrina adecuados para administracion por via intranasal - Google Patents
Un complejo de eletriptan y un derivado de ciclodextrina adecuados para administracion por via intranasalInfo
- Publication number
- PE20010346A1 PE20010346A1 PE2000000648A PE0006482000A PE20010346A1 PE 20010346 A1 PE20010346 A1 PE 20010346A1 PE 2000000648 A PE2000000648 A PE 2000000648A PE 0006482000 A PE0006482000 A PE 0006482000A PE 20010346 A1 PE20010346 A1 PE 20010346A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- eletriptan
- 4so3h
- complex
- derivative
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nanotechnology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
SE REFIERE A UN COMPLEJO DE UNA SAL HEMISULFATO DE ELETRIPTAN Y UN DERIVADO DE SULFOBUTILETER-ß-CICLODEXTRINA DE FORMULA I, DONDE R1a-g, R2a-G, R3a-g SON OH, O(CH2)4SO3H, CON LA CONDICION QUE AL MENOS UNO DE R1a-g ES O(CH2)4SO3H, SIENDO EL NUMERO DE GRUPOS -O(CH2)4SO3H POR MOLECULA DE FORMULA I DENTRO DEL INTERVALO 6,1 A 6,9; PRESENTANDOSE EN UNA RELACION DE 1:1 Y 15:1; TAMBIEN SE REFIERE A UNA FORMULACION QUE COMPRENDE DE 50 mg/g A 120 mg/g DE HEMISULFATO DE ELETRIPTAN; DE 15% A 25% EN RELACION PESO/PESO DE SULFOBUTILETER-ß-CICLODEXTRINA Y ADEMAS COMPRENDE UN ANTIOXIDANTE TAL COMO ACIDO ASCORBICO UTILIZANDOSE 0.25% A 0.8% PESO/PESO, UN DISOLVENTE ADICIONAL TAL COMO GLICEROL UTILIZANDOSE DE 10% A 25% PESO/PESO, UN POLIMERO ORGANICO TAL COMO CARBOXIMETILCELULOSA, POLIVINILPIRROLIDONA UTILIZANDOSE DE 0.05% A UN 20% PESO/PESO, SE PRESENTA EN FORMA DE UNA SOLUCION ACUOSA DE pH 4 A 5. EL ELETRIPTAN O 3-([1-METILPIRROLIDIN-2(R)-IL-METIL)-5-(2-FENILSULFONILETIL)-1H-INDOL ES UN AGONISTA DEL RECEPTOR 5HT1B/1D Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA MIGRANA, HIPERTENSION, EMESIS, DEPRESION, ANSIEDAD
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9915231.6A GB9915231D0 (en) | 1999-06-29 | 1999-06-29 | Pharmaceutical complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010346A1 true PE20010346A1 (es) | 2001-03-26 |
Family
ID=10856302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000648A PE20010346A1 (es) | 1999-06-29 | 2000-06-27 | Un complejo de eletriptan y un derivado de ciclodextrina adecuados para administracion por via intranasal |
Country Status (44)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9915231D0 (en) * | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
| AU2003269965B2 (en) * | 2002-08-20 | 2008-02-21 | Otsuka Pharmaceutical Co., Ltd | Aripiprazole complex formulation and method |
| GB0329918D0 (en) * | 2003-12-24 | 2004-01-28 | West Pharm Serv Drug Res Ltd | Intranasal compositions |
| CN1296391C (zh) * | 2004-03-04 | 2007-01-24 | 中国人民解放军第二军医大学 | 氟代羧烷基环糊精醚类化合物及其制备方法和应用 |
| GB0613925D0 (en) | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| CN101957330B (zh) * | 2010-06-12 | 2013-10-09 | 南京巨环医药科技开发有限公司 | 磺丁基倍他环糊精含量的测定方法 |
| WO2017122161A1 (en) * | 2016-01-15 | 2017-07-20 | Cadila Healthcare Limited | An intranasal composition comprising 5ht1b/1d receptor agonists |
| US20190224171A1 (en) * | 2018-01-22 | 2019-07-25 | Insys Development Company, Inc. | Liquid rizatriptan compositions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| HU210921B (en) | 1990-03-28 | 1995-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them |
| HU211648A9 (en) | 1990-03-28 | 1995-12-28 | Chinoin Gyogyszer Es Vegyeszet | Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same |
| BR9106978A (pt) | 1990-10-15 | 1993-09-28 | Pfizer | Derivados de indol |
| ZA941544B (en) | 1993-03-05 | 1994-10-31 | Hexal Pharma Gmbh | Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same. |
| EP0699079B1 (en) | 1994-03-07 | 2004-09-29 | The Dow Chemical Company | Bioactive and/or targeted dendrimer conjugates comprising genetic materials |
| GB9417310D0 (en) | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
| BR9710289A (pt) | 1996-07-11 | 1999-08-17 | Farmarc Nederland Bv | Composi-Æo farmac-utica contendo sal cido de adi-Æo de medicamento b sico |
| US5998462A (en) | 1996-12-16 | 1999-12-07 | Allelix Biopharmaceuticals Inc. | 5-alkyl indole compounds |
| GB9704498D0 (en) | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Chemical compound |
| ES2163291T3 (es) | 1997-07-03 | 2002-01-16 | Pfizer | Composiciones farmaceuticas que contienen eletriptan hemisulfato y cafeina. |
| GB9816556D0 (en) * | 1998-07-30 | 1998-09-30 | Pfizer Ltd | Therapy |
| GB9915231D0 (en) * | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
-
1999
- 1999-06-29 GB GBGB9915231.6A patent/GB9915231D0/en not_active Ceased
-
2000
- 2000-05-26 CO CO00039185A patent/CO5170494A1/es not_active Application Discontinuation
- 2000-06-02 EP EP00929741A patent/EP1189640B1/en not_active Expired - Lifetime
- 2000-06-02 TR TR2001/03827T patent/TR200103827T2/xx unknown
- 2000-06-02 OA OA1200100328A patent/OA11964A/en unknown
- 2000-06-02 CN CNB008097127A patent/CN1198654C/zh not_active Expired - Fee Related
- 2000-06-02 KR KR1020017016844A patent/KR20020015067A/ko not_active Application Discontinuation
- 2000-06-02 BR BR0011845-1A patent/BR0011845A/pt not_active Application Discontinuation
- 2000-06-02 PL PL00352902A patent/PL352902A1/xx not_active Application Discontinuation
- 2000-06-02 DZ DZ013320A patent/DZ3320A1/fr active
- 2000-06-02 HU HU0201629A patent/HUP0201629A3/hu unknown
- 2000-06-02 ES ES00929741T patent/ES2235879T3/es not_active Expired - Lifetime
- 2000-06-02 YU YU87501A patent/YU87501A/sh unknown
- 2000-06-02 MX MXPA01013274A patent/MXPA01013274A/es active IP Right Grant
- 2000-06-02 AT AT00929741T patent/ATE290884T1/de not_active IP Right Cessation
- 2000-06-02 EE EEP200100697A patent/EE200100697A/xx unknown
- 2000-06-02 JP JP2001505950A patent/JP4454900B2/ja not_active Expired - Fee Related
- 2000-06-02 DE DE60018744T patent/DE60018744T2/de not_active Expired - Lifetime
- 2000-06-02 SK SK1893-2001A patent/SK18932001A3/sk unknown
- 2000-06-02 IL IL14634100A patent/IL146341A0/xx unknown
- 2000-06-02 AU AU47741/00A patent/AU770169B2/en not_active Ceased
- 2000-06-02 NZ NZ515235A patent/NZ515235A/en unknown
- 2000-06-02 UA UA2001129200A patent/UA66932C2/xx unknown
- 2000-06-02 CA CA002376847A patent/CA2376847C/en not_active Expired - Fee Related
- 2000-06-02 CZ CZ20014572A patent/CZ20014572A3/cs unknown
- 2000-06-02 EA EA200101106A patent/EA003908B1/ru not_active IP Right Cessation
- 2000-06-02 WO PCT/IB2000/000746 patent/WO2001000243A1/en active IP Right Grant
- 2000-06-02 GE GE4655A patent/GEP20043377B/en unknown
- 2000-06-02 AP APAP/P/2001/002369A patent/AP2001002369A0/en unknown
- 2000-06-06 PA PA20008496801A patent/PA8496801A1/es unknown
- 2000-06-22 GT GT200000102A patent/GT200000102A/es unknown
- 2000-06-27 UY UY26224A patent/UY26224A1/es not_active Application Discontinuation
- 2000-06-27 PE PE2000000648A patent/PE20010346A1/es not_active Application Discontinuation
- 2000-06-27 AR ARP000103223A patent/AR033337A1/es unknown
- 2000-06-28 TN TNTNSN00142A patent/TNSN00142A1/fr unknown
- 2000-06-28 SV SV2000000112A patent/SV2002000112A/es unknown
- 2000-06-29 EC EC2000003551A patent/ECSP003551A/es unknown
- 2000-06-29 US US09/606,508 patent/US6713461B1/en not_active Expired - Fee Related
-
2001
- 2001-11-16 IS IS6163A patent/IS6163A/is unknown
- 2001-11-26 BG BG106151A patent/BG106151A/xx unknown
- 2001-12-20 ZA ZA200110454A patent/ZA200110454B/xx unknown
- 2001-12-21 HR HR20010951A patent/HRP20010951A2/xx not_active Application Discontinuation
- 2001-12-24 MA MA26450A patent/MA26801A1/fr unknown
- 2001-12-28 NO NO20016430A patent/NO20016430L/no not_active Application Discontinuation
-
2004
- 2004-03-30 US US10/812,440 patent/US20040186076A1/en not_active Abandoned
-
2006
- 2006-04-13 JP JP2006111074A patent/JP2006257091A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| JP2004501930A5 (es) | ||
| EP2266569A3 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
| EP2269610A3 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
| AR058193A1 (es) | Composiciones farmaceuticas | |
| ECSP088239A (es) | Composición de liberación de fármaco sostenida | |
| Jan et al. | Mechanism of rise and decay of thapsigargin-evoked calcium signals in MDCK cells | |
| MX2008009357A (es) | Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion. | |
| NO20083027L (no) | Kontrollert frigivelses-fastformpreparat | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| PE20080374A1 (es) | Composiciones farmaceuticas de ropinirol | |
| CL2009000394A1 (es) | Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
| BR0315315A (pt) | Método para tratar, prevenir ou controlar uma sìndrome mielodisplásica, método para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
| ATE396967T1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
| AR063587A1 (es) | Preparcion liquida que comprende pimobendan | |
| PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
| AR043662A1 (es) | Derivados de guanidina | |
| BRPI0511224A (pt) | método para preparar uma composição contendo antagonistas de opióides, produto contendo antagonistas de opióides, composição contendo antagonistas de opióides, formulação de dosagem injetável, kit, método para prevenir ou tratar um efeito colateral associado com um opióide num paciente, e para tratar ou impedir dor num paciente | |
| PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
| PE20060244A1 (es) | Formulacion farmaceutica de deposito que contiene polietilenglicol de peso molecular menor a 600 daltones | |
| NO20025999D0 (no) | Klart, vandig anestetisk preparat | |
| PE20010346A1 (es) | Un complejo de eletriptan y un derivado de ciclodextrina adecuados para administracion por via intranasal | |
| AR046756A1 (es) | Derivados de hidronopol como agonistas de receptores orl-1 humanos. | |
| BR0307278A (pt) | Formulação oral de liberação imediata, e, método para preparar uma formulação | |
| MX2007008141A (es) | Composicion farmaceutica de sustancias labiles en medio acido. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |